Education
About Us
Working with TipRanks
Follow Us
Biote Corp. (BTMD)
NASDAQ:BTMD
Earnings Data
Report Date
May 12, 2026After Close (Not Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.05Last Year’s EPS
0.37Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced results: the company demonstrated meaningful operational progress (commercial team expansion, strong e-commerce supplement growth, cost reductions, positive operating cash flow and a clear recovery plan) while facing material near-term headwinds in its core procedure business (13% procedure revenue decline), margin pressure from a $1.3M recall-related inventory charge, higher clinic attrition, and lower adjusted EBITDA versus the prior year. Management provided constructive 2026 targets and plans to invest in sales and technology to drive a return to procedure growth, but near-term guidance anticipates mid-to-high single-digit pressure on procedure revenue and a step-up in expenses.Company Guidance
Revenue — Dietary Supplements Growth
Dietary supplement revenue increased 16% year-over-year to $11.7M in Q4 2025, driven primarily by continued growth of the e-commerce channel; management expects dietary supplement revenue to grow at a mid- to high-single-digit rate in 2026.
Commercial Team Rebuild and Practitioner Momentum
Commercial team expanded from approximately 60 to over 90 salespeople since the May reorganization, with plans to grow to ~120 in 2026; training sessions at full capacity and acceleration in practitioner attendance since mid-November indicate improving practitioner recruitment and onboarding momentum—leading indicator for future procedure growth.
Cost Control — SG&A Reduction
Selling, general, and administrative expenses decreased 25.1% to $24.7M in Q4 2025, driven by lower legal expense and a temporary reduction in headcount, helping offset some of the revenue pressure.
Positive Adjusted EBITDA and Cash Generation
Adjusted EBITDA for 2025 was $11.7M with a 25.2% adjusted EBITDA margin; operating cash flow for 2025 was $35.2M and cash and cash equivalents were $24.1M as of 12/31/2025, providing liquidity to fund 2026 investments.
Guidance — Long-term Financial Targets
Company provided 2026 guidance of total revenues above $190M and adjusted EBITDA greater than $38M, signaling management confidence in return to growth and improved profitability over time following investments.
Operational Improvements and Vertical Integration Benefits
Management highlighted strengthened internal processes, improved data analytics, and efficiencies from vertical integration of the 503B manufacturing facility that contributed positively to gross margin excluding recall-related charges.
BTMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BTMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 11, 2026 | $1.72 | $1.54 | -10.47% |
Nov 05, 2025 | $2.93 | $2.84 | -3.07% |
Aug 06, 2025 | $3.86 | $2.92 | -24.35% |
May 07, 2025 | $3.34 | $3.74 | +11.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biote Corp. (BTMD) report earnings?
Biote Corp. (BTMD) is schdueled to report earning on May 12, 2026, After Close (Not Confirmed).
What is Biote Corp. (BTMD) earnings time?
Biote Corp. (BTMD) earnings time is at May 12, 2026, After Close (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BTMD EPS forecast?
BTMD EPS forecast for the fiscal quarter 2026 (Q1) is 0.05.